Omalizumab Subcutaneous and Propranolol Sustained-Release Capsules
Determining the interaction of Omalizumab Subcutaneous and Propranolol Sustained-Release Capsules and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: omalizumab
Brand name: Xolair, Xolair Prefilled Syringe
Synonyms: Omalizumab
Generic Name: propranolol
Brand name: Hemangeol, Inderal LA, Inderal XL, InnoPran XL, Inderal, InnoPran XL
Synonyms: Propranolol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Omalizumab Subcutaneous-Propranolol Tablets
- Omalizumab Subcutaneous-Proprinal
- Omalizumab Subcutaneous-Propulsid
- Omalizumab Subcutaneous-Propulsid (Cisapride Suspension)
- Omalizumab Subcutaneous-Propulsid (Cisapride Tablets)
- Omalizumab Subcutaneous-Propylhexedrine
- Propranolol Sustained-Release Capsules-Ombitasvir, Paritaprevir, and Ritonavir
- Propranolol Sustained-Release Capsules-Ombitasvir, paritaprevir, ritonavir and dasabuvir
- Propranolol Sustained-Release Capsules-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
- Propranolol Sustained-Release Capsules-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Propranolol Sustained-Release Capsules-Omeclamox-Pak
- Propranolol Sustained-Release Capsules-Omega-3 Fatty Acid Capsules